INCYTE CORP
Incyte Corporation is a biopharmaceutical company. Its business strategy focuses on the discovery, development, and commercialization of proprietary therapeutics, primarily in the oncology and inflammation fields. The company's segments include Oncology and Inflammation. Incyte's website is <https://www.incyte.com>, and its ticker symbol is INCY on The Nasdaq Global Select Market. The company filed an amended Form 10-K to correct an administrative error regarding the filing of Exhibit 97.1, Incyte Corporation Policy for Recoupment of Erroneously Awarded Compensation. The correct document is attached as Exhibit 97.1 to the amended filing. No changes were made to the financial statements or other disclosures in the original Form 10-K. Incyte has filed new certifications by its principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act. The company's market value of common stock held by non-affiliates was approximately $1 billion as of June 30, 2023, and there were approximately 111.4 million shares of common stock outstanding as of February 6, 2024. The auditor for the company is PwC.